Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the a...

Descripció completa

Dades bibliogràfiques
Autors principals:	Mease, P, Kavanaugh, A, Coates, L, McInnes, I, Hojnik, M, Zhang, Y, Anderson, J, Dorr, A, Gladman, D
Format:	Journal article
Idioma:	English
Publicat:	BMJ Publishing Group 2017

Ítems similars

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
per: Coates, L, et al.
Publicat: (2019)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
per: Kavanaugh, A, et al.
Publicat: (2024)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
per: Gladman, DD, et al.
Publicat: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
per: Mease, PJ, et al.
Publicat: (2020)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
per: Choy, E, et al.
Publicat: (2007)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
per: Coates, LC, et al.
Publicat: (2021)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
per: Kavanaugh, A, et al.
Publicat: (2005)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
per: Coates, LC, et al.
Publicat: (2024)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
per: Landewé, R, et al.
Publicat: (2019)

Psoriatic arthritis
per: FitzGerald, O, et al.
Publicat: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2023)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
per: Désirée van der Heijde, et al.
Publicat: (2020-02-01)

Classification and outcome measures for psoriatic arthritis
per: Leung, Y, et al.
Publicat: (2018)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
per: Laura C. Coates, et al.
Publicat: (2024-02-01)

Considerations for the definition of remission criteria in psoriatic arthritis
per: Mease, P, et al.
Publicat: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
per: Orbai, A-M, et al.
Publicat: (2019)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
per: Alexis Ogdie, et al.
Publicat: (2023-05-01)

Assessing disease activity in psoriatic arthritis: a literature review
per: Tucker, L, et al.
Publicat: (2018)

Classification and Outcome Measures for Psoriatic Arthritis
per: Ying Ying Leung, et al.
Publicat: (2018-09-01)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
per: Soriano, ER, et al.
Publicat: (2023)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
per: Coates, L, et al.
Publicat: (2017)

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity
per: Pierluigi Macchioni, et al.
Publicat: (2022-12-01)

Methotrexate in psoriasis and psoriatic arthritis
per: Coates, L, et al.
Publicat: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
per: Helliwell, PS, et al.
Publicat: (2022)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
per: Ye, W, et al.
Publicat: (2018)

Sustained very low disease activity and remission in psoriatic arthritis patients
per: Lubrano, E, et al.
Publicat: (2019)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
per: Yazji, SM, et al.
Publicat: (2025)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
per: Strand, V, et al.
Publicat: (2022)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
per: Ennio Lubrano, et al.
Publicat: (2019-08-01)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
per: Silvia Scriffignano, et al.
Publicat: (2023-09-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
per: Coates, L, et al.
Publicat: (2021)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
per: Coates, L, et al.
Publicat: (2018)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
per: Mease, PJ, et al.
Publicat: (2019)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
per: Atul Deodhar, et al.
Publicat: (2022-07-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
per: Coates, L, et al.
Publicat: (2018)

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
per: Rubén Queiro, et al.
Publicat: (2017-03-01)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
per: D.D. Gladman
Publicat: (2011-09-01)

Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis
per: Alexander Egeberg, et al.
Publicat: (2018-03-01)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
per: Laura C. Coates, et al.
Publicat: (2018-08-01)